Hisham Allababidi, MD
Endocrinology, Diabetes & Metabolism · Indianapolis, INNPI 1710913470
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $165,258 of the $195,104 with a category attached, or 84.7%. Novo Nordisk accounts for 60.3% of it on its own, with 45 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 885 payments — averaging $220.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$118K
- Boehringer Ingelheim$30K
- Johnson & Johnson$24K
- Lilly USA, LLC$13K
- Abbott$2K
- Medtronic$1K
- plus $7K from 40 others
What the payments were for
- Consulting fees$5,6153%
- Speaking & faculty fees$165,25885%
- Travel & lodging$11,6936%
- Food & beverage$12,3626%
- Education$570%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$51,648
- JARDIANCE$40,450
- RYBELSUS$36,219
- INVOKANA$23,534
- Tresiba$9,745
- Xultophy 100/3.6$3,618
- FreeStyle Libre Pro$1,994
- JUXTAPID$1,200
- MINIMED 780G$725
- iLet Bionic Pancreas$316
- EVENITY$250
- Prolia$125
- Minimed 630G$121
- FARXIGA$120
- Minimed 670G System$115
- iLet Insulin Infusion Kit Inset$105
- iLet Insulin Infusion Kit Contact Detach$105
How this compares
$195,104 in reported general payments places this provider in the 95th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 232 | $369,169 |
| OzempicSemaglutide | 173 | $228,434 |
| JardianceEmpagliflozin | 176 | $196,184 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $67,001 |
| JanuviaSitagliptin Phosphate | 89 | $66,074 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $65,176 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $55,718 |
| FarxigaDapagliflozin Propanediol | 46 | $50,109 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $47,768 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 53 | $47,044 |
| Teriparatide | 15 | $44,851 |
| TrulicityDulaglutide | 33 | $43,057 |
| TymlosAbaloparatide | 13 | $35,425 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 74 | $27,745 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $22,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $12,771 | $412,225265 claims |
| Novo NordiskOzempic, Rybelsus | $117,672 | $243,890185 claims |
| Boehringer IngelheimJardiance, Tradjenta | $29,654 | $216,034193 claims |
| MerckJanuvia | $370 | $66,07489 claims |
| AstraZenecaFarxiga | $481 | $50,10946 claims |
| Radius Health, Inc.Tymlos | $31 | $35,42513 claims |
| AbbVieSynthroid | $217 | $3,26032 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $1,912208 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Indianapolis
- Ernest AsamoahIndianapolis$959K
- Michael EconsIndianapolis$74K
- Carmella Evans-MolinaIndianapolis$55K
- Manuel Bello SeguraIndianapolis$44K
- Moazzam HabibIndianapolis$29K
- James EdmondsonIndianapolis$10K
- James ScheidlerIndianapolis$8K
- Cary MariashIndianapolis$6K
- Jayender ChintaparthiIndianapolis$5K
- Munro PeacockIndianapolis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.